Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Dtx Pharma Inc.
Headquarters: San Diego, CA, United States of America
Website: N/A
Year Founded: 2017
Status: Acquired
BioCentury | Dec 20, 2024
Emerging Company Profile
City: Taking RNAi beyond the liver
Maraganore’s latest RNA company pairs targeting tech with trigger molecules a fraction of the size of Alnylam’s
BioCentury | Jan 23, 2024
Data Byte
Centerview advised most of the sellers in 2023’s largest M&A deals
Centerview Partners acted as an adviser to 64% of the biotechs acquired in $1B+ deals
BioCentury | Jan 4, 2024
Management Tracks
Lanthaler leaving Evotec as CEO
Plus: Morphic’s CEO Tipirneni returns and more from Kojin, Harvard, Star, Novavax, Entrada, Brii, Switch, SmartCella
BioCentury | Oct 13, 2023
Product Development
Less is more at NIBR. Narasimhan on the R&D makeover at Novartis
Bringing focus in R&D is central to the CEO’s plans to mark territories of leadership
BioCentury | Jul 18, 2023
Deals
July 17 Quick Takes: Novartis acquires DTx for $500M up front
Plus: FDA approves AZ and Sanofi’s RSV prophylactic, and updates from Apellis, J&J, Travere and Acumen
BioCentury | Nov 2, 2022
Management Tracks
New heads of commercial, legal at ADC
Plus Antares vet Powell lands at Lava, and updates from CymaBay, Lineage, CARsgen and more
BioCentury | Jun 29, 2022
Management Tracks
New CEOs at Dunad and Cargene
Plus Vickers becomes CEO at MSKCC, and updates from Paradigm and DTx
BioCentury | Jun 1, 2022
Management Tracks
Zentalis co-founder Gallagher now president
Plus DTx hires Huang as CMO and updates from neoX, Altoid and more
BioCentury | Feb 2, 2022
Emerging Company Profile
BioCentury’s 2021 class of emerging companies
An innovation showcase of protein degraders, RNA therapeutics, delivery vectors and gene modifiers
BioCentury | Jun 7, 2021
Management Tracks
New hires at Merck KGaA's neurology & immunology business; plus Repertoire, Kinnate, Allakos, Intercept and more
Amy Mahery, a 17-year veteran at Merck KGaA (Xetra:MRK), was named the pharma’s SVP and head of the neurology and immunology global business franchise; she was SVP and head of global market
Items per page:
1 - 10 of 12